JonesTrading analyst Matthew Cross maintained a Buy rating on Aldeyra Therapeutics (ALDX – Research Report) today and set a price target of $34.00. The company’s shares closed last Monday at $4.99, close to its 52-week low of $4.31.
According to TipRanks.com, Cross is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.9% and a 37.5% success rate. Cross covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Catalyst Biosciences, and Abeona Therapeutics.
Currently, the analyst consensus on Aldeyra Therapeutics is a Moderate Buy with an average price target of $33.50.
Based on Aldeyra Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $18.72 million. In comparison, last year the company had a GAAP net loss of $10.81 million.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes.